| Arthur O. Tzianabos |
Presently, Arthur O. Tzianabos is Chairman for Homology Medicines, Inc. and Venture Partner at 5AM Venture Management LLC. Dr. Tzianabos is also on the board of Alliance for Regenerative Medicine, Stoke Therapeutics, Inc. and Oxford Biomedica Solutions LLC and Member-Development Board at the University of New Hampshire.
He previously was Chairman at Akouos, Inc., President & Chief Scientific Officer at OvaScience, Inc., Senior VP, Head-Research & Early Development at Shire Plc, Senior VP, Head-Research & Early Development at Shire Pharmaceuticals, Inc. and Associate Professor & Member at Harvard Medical School.
Arthur O. Tzianabos received an undergraduate degree from Boston College and a doctorate from the University of New Hampshire. |
| Deborah Kinch |
Deborah Kinch is Chief Development Officer at Homology Medicines, Inc.
In the past Dr. Kinch was Head-Early Regulatory Sciences at Biogen, Inc.
She received an undergraduate degree from Mount Holyoke College and a doctorate from Yale University. |
| Michael Blum |
Michael Blum is Chief Commercial Officer of Homology Medicines, Inc.
In his past career Mr. Blum occupied the position of Head-Market Access at Sarepta Therapeutics, Inc. and Head-Commercial Operations at Zafgen, Inc.
Mr. Blum received an undergraduate degree from College of the Holy Cross (Massachusetts) and an MBA from Babson College. |
| Paul G. Alloway |
Currently, Paul G. Alloway occupies the position of President, CEO, COO & Secretary at Homology Medicines, Inc.
Dr. Alloway previously held the position of Secretary & Head-Legal at Foghorn Therapeutics, Inc. and Vice President & Senior Counsel at DRI Capital, Inc.
Paul G. Alloway received an undergraduate degree from the University of Toronto, a doctorate from Dartmouth College and a graduate degree from Suffolk University Law School. |
| Alise S. Reicin |
Presently, Alise S. Reicin holds the position of President, Chief Executive Officer & Director at Tectonic Therapeutic, Inc. and Venture Advisor at Israel Biotech Fund. Dr. Reicin is also on the board of Sharsheret, Inc., Homology Medicines, Inc. and Sana Biotechnology, Inc.
In her past career Alise S. Reicin was VP-Oncology Program & Pipeline Leadership at Merck & Co., Inc., Head-Global Clinical Development at EMD Serono, Inc., President-Global Clinical Development at Celgene Corp. and Member of Columbia University Vagelos College of Physicians & Surgeons.
She received an undergraduate degree from Barnard College and a doctorate from Harvard Medical School. |
| Richard James Gregory |
Richard James Gregory is on the board of Homology Medicines, Inc. and CANbridge Pharmaceuticals Inc.
Dr. Gregory previously occupied the position of Chief Scientific Officer & Executive VP-Research at ImmunoGen, Inc., Head-Research & Development at Genzyme Corp. and Chief Scientific Officer & Director at Canbridge Pharmaceuticals, Inc. (United States).
Dr. Gregory received a doctorate from the University of Massachusetts and an undergraduate degree from Virginia Polytechnic Institute & State University. |
| Jeffrey V. Poulton |
Currently, Jeffrey V. Poulton occupies the position of Chief Financial Officer & Executive Vice President at Alnylam Pharmaceuticals, Inc. Mr. Poulton is also on the board of EIP Pharma, Inc., Homology Medicines, Inc., Alnylam UK Ltd. and CervoMed, Inc.
In his past career Jeffrey V. Poulton occupied the position of Chief Financial Officer of Indigo Ag, Inc. and Chief Financial Officer & Executive Director at Shire Plc.
He received an undergraduate degree from Duke University and an MBA from Kelley School of Business. |
| Matthew R. Patterson |
Founder of Astellas Gene Therapies, Inc., Matthew R. Patterson is a businessperson who has been at the helm of 6 different companies and occupies the position of Chairman of Vor Biopharma, Inc., Executive Chairman of Iris Medicine, Inc. and Executive Chairman at Remix Therapeutics, Inc. He is also on the board of Gilda's Club New York City, Inc., Homology Medicines, Inc., Modis Therapeutics, Inc. and 5:01 Acquisition Corp.
Mr. Patterson previously was President for Amicus Therapeutics, Inc., Vice President-Commercial Planning at BioMarin Pharmaceutical, Inc., Chairman & Chief Executive Officer for Astellas Gene Therapies, Inc., Senior Associate-Regulatory Affairs at Genzyme Corp., Entrepreneur-in-Residence at OrbiMed Advisors Private Equity and Chairman for Alliance for Regenerative Medicine.
He received an undergraduate degree from Bowdoin College. |
| Steven H. Gillis |
Steven H. Gillis is a businessperson who founded Immunex Corp. and Corixa Corp. and who has been at the head of 20 different companies. Presently, Dr. Gillis holds the position of Chairman at Theraclone Sciences, Inc., Chairman of Codiak BioSciences, Inc., Chairman of VBI Vaccines, Inc., Chairman for eGenesis, Inc., Chairman at Hibercell, Inc., Chairman at Walden Biosciences, Inc., Chairman at Mozart Therapeutics, Inc., Chairman of hC Bioscience, Inc., Chairman at TFC Therapeutics, Inc., Investment Committee Member at W Fund Management LLC and Senior Advisor at Accelerator Services Corp. Dr. Gillis is also Managing Director at ARCH Venture Partners LLC and on the board of 18 other companies.
In his past career Dr. Gillis held the position of Chairman of Lycera Corp., Executive Chairman of Viral Logic Systems Technology Corp., Chairman of PhaseRx, Inc., Chairman at Qwell Pharmaceuticals, Inc., Chairman for Nohla Therapeutics, Inc., Director, Chief Executive & Scientific Officer at Immunex Corp., Chairman & Chief Executive Officer of Corixa Corp., Executive Chairman, President & CEO at Emergent Product Development Seattle and Chairman of XORI Corp.
Steven H. Gillis received a doctorate from Dartmouth College and an undergraduate degree from Williams College. |
| Mary T. Thistle |
Mary T. Thistle is on the board of Cocoon Biotech, Inc. and 4 other companies. In the past she was Senior Vice President-Business Development at Cubist Pharmaceuticals LLC, Consultant at Yoshida & Sokolski PC, Special Advisor at Bill & Melinda Gates Medical Research Institute, Chief Financial & Accounting Officer of Dimension Therapeutics, Inc., Senior Vice President-Business Development at ViaCell, Inc., Accountant at Deloitte & Touche LLP, Principal at Sierra Research & Technology, Inc. and Senior Vice President-Business Development of PerkinElmer, Inc.
Ms. Thistle received an undergraduate degree from the University of Massachusetts. |
